/

2023 Summit on Cancer Health Disparities (SCHD)

1 min read

SEATTLE, WA – The Binaytara Foundation, a non-profit organization dedicated to improving healthcare in underserved communities, is proud to announce the 2023 Summit on Cancer Health Disparities (SCHD), which will take place on April 28-30, 2023, at the Grand Hyatt in Seattle, WA.

 

SCHD is a three-day event that brings together healthcare professionals, researchers, advocates, and patients from around the world to discuss the latest advancements in cancer research, treatment, and care. The summit aims to address cancer health disparities and improve access to quality care for underserved populations.

 

The 2023 Summit will feature keynote speakers, panel discussions, and poster presentations, all focused on the theme of “Reframing and Addressing Barriers to Adoption of Precision Oncology.” Led by conference chairs Drs. Ana Maria Lopez, Hannah Linden, and David Aboulafia, topics will include immunotherapy and cellular therapy, novel therapies in cancer, access to cancer care in LMIC – navigating current challenges, addressing disparities in diagnostics, artificial intelligence and machine learning, among others.

 

“We are excited to bring together experts in cancer care and health disparities to share their knowledge and experiences at the 2023 Summit on Cancer Health Disparities,” said Dr. Binay Shah, President of the Binaytara Foundation. “We believe that by working together, we can address the inequalities in cancer care and improve outcomes for all patients, regardless of their socioeconomic status, race, or ethnicity.”

 

The Binaytara Foundation is committed to providing education, research, and advocacy to improve healthcare for underserved communities. The SCHD Summit is one of the many initiatives undertaken by the Foundation to promote health equity and reduce health disparities worldwide.

 

Registration for the 2023 Summit on Cancer Health Disparities is now open. Register here! 

Latest from Blog

HER2CLIMB-02

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Tucatinib, a HER2-directed tyrosine kinase

INAVO120 trial

By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center   Development of endocrine resistance remains